Sugi Predict

Sugi Predict / Compounds / SCHEMBL4466084

SCHEMBL4466084

SCHEMBL4466084

CCS(=O)(=O)N1CCC(Nc2sc(C(=O)c3cc(-c4ccccc4)no3)c(N)c2C(N)=O)C1

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ USP30 Q70CQ3 8/20 0.41
▸ LMNA P02545 1/20 0.36
▸ TP53 P04637 1/20 0.36
▸ MAPT P10636 1/20 0.36
▸ RAB9A P51151 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ PTPN1 P18031 1/20 0.35
▸ JAK1 P23458 1/20 0.34
▸ JAK3 P52333 1/20 0.34
▸ SMYD3 Q9H7B4 1/20 0.34
▸ IKBKB O14920 1/20 0.34
▸ CHUK O15111 1/20 0.34
▸ CDK1 P06493 1/20 0.34
▸ CDK4 P11802 1/20 0.34
▸ CCND1 P24385 1/20 0.34
▸ CDK2 P24941 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4467806 0.94 JAK3 (0.41) USP30LMNATP53MAPTRAB9A
SCHEMBL4469460 0.92 USP30 (0.40) USP30LMNATP53MAPTSMN1; SMN2
SCHEMBL4474610 0.89 USP30 (0.43) USP30LMNATP53MAPTRAB9A
SCHEMBL4485824 0.88 USP30 (0.45) USP30MAPTSMN1; SMN2
SCHEMBL3816591 0.84 LMNA (0.40) USP30LMNATP53MAPTRAB9A
SCHEMBL4473863 0.81 USP30 (0.45) USP30MAPTSMN1; SMN2JAK1JAK3
SCHEMBL3816399 0.80 CHEK1 (0.41) USP30LMNATP53MAPT
SCHEMBL4466293 0.79 USP30 (0.44) USP30MAPTSMN1; SMN2PTPN1JAK1
SCHEMBL3818041 0.79 KDM4E (0.37) USP30LMNATP53MAPTRAB9A
SCHEMBL4486946 0.78 KDM4E (0.41) LMNATP53MAPTRAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8470821-B2 PDE4B inhibitors and uses therefor PLEXXIKON INC. (US) 2013-06-25 — — US disclosed
US-8470821-B2 PDE4B inhibitors and uses therefor PLEXXIKON INC. (US) 2013-06-25 — — US disclosed
US-8470821-B2 PDE4B inhibitors and uses therefor PLEXXIKON INC. (US) 2013-06-25 — — US disclosed
US-20090286793-A1 PDE4B INHIBITORS AND USES THEREFOR PLEXXIKON, INC. 2009-11-19 — — US disclosed
US-20090286793-A1 PDE4B INHIBITORS AND USES THEREFOR PLEXXIKON, INC. 2009-11-19 — — US disclosed
US-20090286793-A1 PDE4B INHIBITORS AND USES THEREFOR PLEXXIKON, INC. 2009-11-19 — — US disclosed
US-7585859-B2 PDE4B inhibitors and uses therefor PLEXXIKON, INC. (US) 2009-09-08 — — US disclosed
US-7585859-B2 PDE4B inhibitors and uses therefor PLEXXIKON, INC. (US) 2009-09-08 — — US disclosed
US-7585859-B2 PDE4B inhibitors and uses therefor PLEXXIKON, INC. (US) 2009-09-08 — — US disclosed
US-20060041006-A1 PDE4B inhibitors and uses therefor PLEXXIKON, INC. 2006-02-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286793-A1 PDE4B INHIBITORS AND USES THEREFOR PDE4B, PDE7B, PDE4A USP30 2232/4885LMNA 2349/4885TP53 4190/4885
US-20060041006-A1 PDE4B inhibitors and uses therefor PDE4B, PDE7B, PDE4A USP30 2232/4885LMNA 2349/4885TP53 4190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.